NCT00109395View on ClinicalTrials.gov

Lorazepam Sedation for Critically Ill Children

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Critical Illness
Interventions
DRUG

Lorazepam

Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score

DRUG

Midazolam

Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score

DRUG

Lorazepam CI

Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score

Trial Locations (1)

44106-6010

Case Western Reserve University, Cleveland

All Listed Sponsors
collaborator

Case Western Reserve University

OTHER

lead

The Emmes Company, LLC

INDUSTRY

NCT00109395 - Lorazepam Sedation for Critically Ill Children | Biotech Hunter | Biotech Hunter